Compare Apple Inc (AAPL) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance

AAPL trades at $310.66, down 0.64% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals including a 26.91% net margin and consistent earnings beats. Revenue grew to $416.16B in 2025, and analyst consensus is a Buy with a $329.62 price target. Recent news highlights AI potential via 2.5B active devices and Gemini partnership, though store closures and union disputes pose headwinds.

The stock offers upside to consensus targets with robust cash flow and profitability, but high valuations (P/E 37.61) and competitive pressures warrant caution. Near-term focus is on Q2 2026 earnings against a $1.88 EPS expectation, with institutional activity mixed amid broader market rotation concerns.

AMLX trades at $17.97, down 1.64% today, with strong analyst support showing 91% buy ratings and a $30.50 consensus price target representing 70% upside potential. The stock shows bullish technical momentum with positive moving average signals, though RSI levels suggest some overbought conditions. Recent earnings showed mixed results with a Q1 2026 miss after two previous beats, while the company continues advancing its pipeline with Phase 3 data for avexitide expected in Q3 2026.

Despite negative profitability metrics and cash burn, AMLX maintains strong institutional confidence with 11 analysts covering the stock. The key catalyst remains the upcoming Phase 3 avexitide readout, though risks include ongoing class action litigation and the company's negative cash flow from operations. Current valuation at 7.31x book value reflects optimism around pipeline assets rather than current financial performance.